Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2)

3D Modeling of Epithelial Tumors-The Synergy between Materials Engineering, 3D Bioprinting, High-Content Imaging, and Nanotechnology




Julkaisun tekijätTrivedi Poonam, Liu Rui, Bi Honhjie, Xu Chunlin, Rosenholm Jessica M, Åkerfelt Malin

KustantajaMDPI

Julkaisuvuosi2021

JournalInternational Journal of Molecular Sciences

Tietokannassa oleva lehden nimiINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Lehden akronyymiINT J MOL SCI

Artikkelin numeroARTN 6225

Volyymi22

Julkaisunumero12

Sivujen määrä27

DOIhttp://dx.doi.org/10.3390/ijms22126225

Verkko-osoitehttps://doi.org/10.3390/ijms22126225

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/66436752


Tiivistelmä
The current statistics on cancer show that 90% of all human cancers originate from epithelial cells. Breast and prostate cancer are examples of common tumors of epithelial origin that would benefit from improved drug treatment strategies. About 90% of preclinically approved drugs fail in clinical trials, partially due to the use of too simplified in vitro models and a lack of mimicking the tumor microenvironment in drug efficacy testing. This review focuses on the origin and mechanism of epithelial cancers, followed by experimental models designed to recapitulate the epithelial cancer structure and microenvironment, such as 2D and 3D cell culture models and animal models. A specific focus is put on novel technologies for cell culture of spheroids, organoids, and 3D-printed tissue-like models utilizing biomaterials of natural or synthetic origins. Further emphasis is laid on high-content imaging technologies that are used in the field to visualize in vitro models and their morphology. The associated technological advancements and challenges are also discussed. Finally, the review gives an insight into the potential of exploiting nanotechnological approaches in epithelial cancer research both as tools in tumor modeling and how they can be utilized for the development of nanotherapeutics.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2022-07-04 at 18:35